Southern Tier Cancer Care

When time is of essence and every moment counts, Southern Tier Cancer Care is hereā€¦.

Welcome to STCC!

We realize that you are apprehensive and fearful. By providing professional assistance through education, the latest approved treatments available and most importantly, compassionate care, we are dedicated to guiding patients to hope, help, and healing.

Southern Tier Cancer Care Team is Committed to
Excellence in Providing Comprehensive, Up to date,
Compassionate and Quality care for Cancer Patients.


Please proceed immediately to the nearest emergency room for any medical emergencies especially fever greater than or equal to 100.4 while on chemotherapy.If you need to reach Dr Soni immediately for problems related to cancer or chemotherapy,

Please call the answering service at (716) 559 1105.

Please call your primary physician or emergency room at Olean General Hospital at (716) 375 4149 for any urgent concerns after office hours or if Dr Soni is away.


News & Updates


Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma [Gastrointestinal Cancer]


To evaluate the efficacy and safety of high-dose, hypofractionated proton beam therapy for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).

Materials and Methods

In this single-arm, phase II, multi-institutional study, 92 patients with biopsy-confirmed HCC or ICC, determined to be unresectable by multidisciplinary review, with a Child-Turcotte-Pugh score (CTP) of A or B, ECOG performance status of 0 to 2, no extrahepatic disease, and no prior radiation received 15 fractions of proton therapy to a maximum total dose of 67.5 Gy equivalent. Sample size was calculated to demonstrate > 80% local control (LC) defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 criteria at 2 years for HCC patients, with the parallel goal of obtaining acceptable precision for estimating outcomes for ICC.


Eighty-three patients were evaluable: 44 with HCC, 37 with ICC, and two with mixed HCC/ICC. The CTP score was A for 79.5% of patients and B for 15.7%; 4.8% of patients had no cirrhosis. Prior treatment had been given to 31.8% of HCC patients and 61.5% of ICC patients. The median maximum dimension was 5.0 cm (range, 1.9 to 12.0 cm) for HCC patients and 6.0 cm (range, 2.2 to 10.9 cm) for ICC patients. Multiple tumors were present in 27.3% of HCC patients and in 12.8% of ICC patients. Tumor vascular thrombosis was present in 29.5% of HCC patients and in 28.2% of ICC patients. The median dose delivered to both HCC and ICC patients was 58.0 Gy. With a median follow-up among survivors of 19.5 months, the LC rate at 2 years was 94.8% for HCC and 94.1% for ICC. The overall survival rate at 2 years was 63.2% for HCC and 46.5% ICC.


High-dose hypofractionated proton therapy demonstrated high LC rates for HCC and ICC safely, supporting ongoing phase III trials of radiation in HCC and ICC.

February 2, 2016

NCI News

Inflammatory Breast Cancer

A fact sheet about the diagnosis and treatment of inflammatory breast cancer (IBC), an uncommon type of cancer in which the breast becomes red, swollen, and warm.

January 15, 2016

ACE News

HPV vaccination: A public health priority

Cancer Centers issue consensus statement urging action

January 27, 2016
Cancer Death Rate Continues Steady Drop

More than 1.7 million cancer deaths averted between 1991 and 2012

January 7, 2016
Cancer Death Rate Continues Steady Drop

More than 1.7 million cancer deaths averted between 1991 and 2012

January 7, 2016